Welcome to our dedicated page for VARIAN MEDICAL news (Ticker: VAR), a resource for investors and traders seeking the latest updates and insights on VARIAN MEDICAL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VARIAN MEDICAL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VARIAN MEDICAL's position in the market.
Varian has announced the release date for its third quarter fiscal year 2020 earnings. The results will be disclosed after market close on August 5, 2020. Following the announcement, a teleconference will take place at 1:30 p.m. Pacific Time. Investors can dial in to access the call or join via the live webcast available on the company’s website. This session allows stakeholders to gain insights into Varian's financial performance and business strategies.
Summary not available.
Results from the SABR-COMET study, published June 2, 2020, indicate that stereotactic ablative radiotherapy (SABR) significantly improves overall survival in patients with oligometastatic cancers. Patients receiving SABR showed a 22-month increase in 5-year median overall survival, equating to a 24.6% absolute survival benefit over standard care. The findings support SABR as a viable treatment option and suggest a shift in treatment paradigms for low burden metastatic disease. Ongoing trials aim to further validate these benefits.